Stealth BioTherapeutics (MITO) Stock Price, News & Analysis

Company Overview

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Key Stats

• Today's Range: $0.32 to $0.32
• 50-Day Range: $0.31 to $0.32
• 52-Week Range: $0.16 to $1.03
• Volume: N/A
• Average Volume: 946,105 shs
• Market Capitalization: $23.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MITO Stock Analysis - Frequently Asked Questions

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) released its earnings results on Thursday, August, 5th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.01.

When did Stealth BioTherapeutics IPO?

Stealth BioTherapeutics (MITO) raised $81 million in an initial public offering on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

What other stocks do shareholders of Stealth BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stealth BioTherapeutics investors own include Tesla (TSLA), TherapeuticsMD (TXMD), NIO (NIO), Plug Power (PLUG), Allena Pharmaceuticals (ALNA), SCYNEXIS (SCYX) and Tonix Pharmaceuticals (TNXP).

Company Calendar

• Last Earnings: 8/05/2021
• Today: 6/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MITO
• CIK: 1696396
• Web: www.stealthbt.com
• Phone: 617-600-6888
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.53 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -142.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.68
• Quick Ratio: 3.68

Sales & Book Value

• Annual Sales: $21.09 million
• Price / Sales: 1.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.79) per share
• Price / Book: -0.41

Miscellaneous

• Outstanding Shares: 73,552,000
• Free Float: N/A
• Market Cap: $23.54 million
• Optionable: Not Optionable
• Beta: 1.46